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S U M M A R Y
Objectives: Persistence of infection with high-risk Human papillomaviruses (HR-HPV) increases the risk
of incident and progressive precancerous lesions of the cervix. Rates of HR-HPV persistence have been
shown to be increased among HIV-infected adult women, however there is a paucity of literature
addressing HPV persistence in the young HIV-infected population. We compared rates of HR-HPV
persistence between HIV-infected and HIV-uninfected young women.
Methods: We obtained self-collected vaginal swabs at six-month intervals from 50 HIV-uninfected and
33 HIV-infected young women recruited through a community youth center (age 17-21 years) and
compared rates of HR-HPV persistence. HR-HPV testing was conducted using the Roche’s Linear Array1
HPV Test.
Results: Eighty-three prevalent (upon baseline testing) and incident (upon subsequent testing)
individual HR-HPV infections were identiﬁed among 43 members of the cohort (23 HIV-uninfected
and 20 HIV-infected). At twelve months, 19% of baseline HR-HPV infections continued to be present with
a statistically signiﬁcant difference between HIV-uninfected and HIV-infected participants (4% versus
31%; p=0.01).
Conclusions: HIV-infected young women in our cohort had a seven-fold increased rate of persistence of
HR-HPV overall at 12 months, indicating an increased risk for incident and progressive precancerous
lesions. Identiﬁcation of persistent infection with HR-HPV may complement cytological ﬁndings in
determining the need for colposcopy.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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High-risk Human papillomaviruses (HR-HPV) cause cervical
cancer1,2. While most infections with HR-HPV are transient3 some
may persist for six months or longer. Persistence of infection with* Corresponding author. 601 Elmwood Avenue, Box 655, Department of Emergency
Medicine, University of Rochester, Rochester, NY, 14534 USA. Tel.: +585 275 1198;
fax: +585 276 1123.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).HR-HPV is associated with increased incidence of precancerous
squamous intraepithelial lesions (SILs) of the cervix4, decreased
rates of regression of SILs5, increased rates of progression of SILs6,
and increased risk of invasive cervical cancer7.
Invasive cervical cancer is an AIDS-deﬁning illness8. Infection
with HIV signiﬁcantly impacts the natural history of HPV
infection. Among HIV-infected women, rates of persistent HR-
HPV infection are increased multifold9. HIV-infected young
women are physiologically and behaviorally different than adults,
and the impact of HIV on persistence of HR-HPV infections in this
age group is understudied. The aim of the present study was to
compare rates of HR-HPV persistence between HIV-infected and
HIV-uninfected young women recruited through a community
youth center.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Between October 2012 and January 2014, we enrolled 50 HIV-
uninfected and 33 HIV-infected sexually active South African
females age 17-21 years (M = 19.06 years; S.D. = 1.48; IQR = 18.00 –
20.00) into a longitudinal study in which self-collected vaginal
swabs for HPV DNA analysis were obtained at six-month intervals.
Study participants were enrolled through a youth community
center in Masiphumelele, a township in Cape Town, South Africa.
All participants signed informed consent (age 18 years and older)
or signed adolescent assent documents (age 17 years) to
accompany parental consent forms. This study was approved by
the Research Subjects Review Board at the University of Rochester
and the Human Research Ethics Committee at the University of
Cape Town.
For self-sampling, patients were instructed to insert a Dacron1
swab high into the vagina and twirl it for 10 seconds. Self-sampling
was conducted in private. Samples were stored in Digene transport
medium, and DNA was extracted using the MagNA Pure Compact
Nucleic Acid Isolation Kit (Roche Diagnostics). HPV genotyping was
conducted using Roche’s Linear Array1 HPV Test. This kit detects
37 HPV genotypes including all oncogenic HPV types identiﬁed by
the International Agency for Research on Cancer (IARC)2. We
deﬁned HR-HPV to include the 13 genotypes designated by IARC to
have sufﬁcient evidence to cause cervical cancer (types 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59) and to have strong mechanistic
evidence for cervical cancer (type 68)2.
All prevalent HR-HPV infections identiﬁed upon baseline
testing and all incident HR-HPV infections identiﬁed upon
subsequent testing were assessed for type-speciﬁc HR-HPV
persistence. Persistence was deﬁned as presence of type-speciﬁc
HR-HPV DNA in (a) both components of any sequential pair of
specimens (e.g., t1 and t2) or (b) both components of any pair of
specimens collected 12 months apart (e.g., t2 and t4). Chi-square
tests for independence were used to examine overall and type-
speciﬁc differences in persistence between HIV-uninfected and
HIV-infected participants (Table 1).
3. Results
Eighty-three prevalent (upon baseline testing) and incident
(upon subsequent testing) individual HR-HPV infections were
identiﬁed among 43 members of the cohort (23 HIV-uninfected
and 20 HIV-infected). The other 40 members of our cohortTable 1
Comparing HR-HPV Persistence Across HIV Status
HIV Positive
n (%)
HIV Negative
n (%)
p – valuea
6 Month Follow-up
All HR-HPV Persistent 16 (33%) 7 (21%) p = 0.23
Cleared 33 (67%) 27 (79%)
HPV16 or 18 Persistent 4 (40%) 2 (29%) p = 0.63
Cleared 6 (60%) 5 (71%)
Non-Vaccine HR-HPV
Persistent
12 (40%) 5 (29%) p = 0.26
Cleared 27 (60%) 22 (71%)
12 Month Follow-up
All HR-HPV Persistent 9 (31%) 1 (4%) p = 0.01
Cleared 20 (69%) 24 (96%)
HPV16 or 18 Persistent 3 (38%) 0 (0%) p = 0.07
Cleared 5 (63%) 7 (100%)
Non-Vaccine HR-HPV
Persistent
6 (29%) 1 (6%) p = 0.06
Cleared 15 (71%) 17 (94%)
a p-values based on Pearson x2 with 1 degree of freedom (2 X 2 analyses).(27 HIV-uninfected and 13 HIV-infected) tested negative for HR-
HPV throughout the study period. Overall, 27% of these infections
were persistent at six months (21% among HIV-uninfected and
33% among HIV-infected, p=0.23). At twelve months, 19% of
baseline HR-HPV infections continued to be present with a
statistically signiﬁcant seven-fold difference in persistence
between HIV-uninfected and HIV-infected participants (4% versus
31%; p=0.01). Rates of persistence across HIV status are summa-
rized in Table 1.
HIV-infected youth were slightly older (mean age 19.91 years,
SD = 1.13) than HIV-uninfected youth (mean age 18.44 years,
SD = 1.40), p<0.05, however, there was no difference in number
of lifetime sexual partners or number of sexual partners in the last
six months across HIV status. The average CD4 count among all
HIV-infected participants was 471/mm3 (IQR= 395 - 508; CD4
counts were not available for 6 participants). Nine of the 33 HIV-
infected participants in our cohort were on anti-retroviral therapy
(ART). Use of ART and CD4 count were not found to be signiﬁcantly
associated with HR-HPV infection.
The overall incidence rate of HR-HPV infection among study
participants without HR-HPV infection upon baseline testing was
found to be 743 new HR-HPV infections per 100 person-years.
Similar rates of persistence were found for vaccine genotypes
(HPV 16 and 18) and non-vaccine high-risk genotypes. All 13 HR-
HPV genotypes were found among our cohort upon initial testing.
At baseline, types 16, 52, and 68 were most commonly identiﬁed.
At six months, types 16, 39, and 45 were most likely to found to
be persistent, and at 12 months types 16 and 52 were most
likely found to be persistent. Due to inadequate power we did not
identify statistically signiﬁcant differences in type-speciﬁc persis-
tence between groups.
4. Discussion
HIV-infected young women in our cohort had a seven-fold
increased rate of persistence of HR-HPV overall at 12 months,
indicating an increased risk for incident and progressive precan-
cerous lesions. Although CD4 counts among the HIV-infected
young women in our cohort were relatively high, the increased risk
of HR-HPV persistence compared to their HIV-uninfected counter-
parts highlights the importance of immune control of HPV
infection.
Identiﬁcation of persistent infection with HR-HPV may
complement cytological ﬁndings in determining the need for
colposcopy. Although HPV DNA testing is currently recom-
mended only for older women without HIV infection10, it may
contribute to optimal cervical cancer screening among young
HIV-infected women given their increased risk for invasive
cervical cancer.
Our study is limited by a modest sample size and relatively brief
follow-up period. Enlargement and further follow-up of this cohort
with additional serial HPV DNA testing and cervical cytology
testing will provide greater insight into the relationship between
HR-HPV persistence and the incidence and progression of SILs in
HIV-infected young women.
Conﬂict of Interest Statement: None of the authors have a
conﬂict of interest to disclose.
Ethical Approval: This study was approved by the Research
Subjects Review Board at the University of Rochester and the
Human Research Ethics Committee at the University of Cape
Town.
Source of funding: This work was supported by the National
Institute of Allergy and Infectious Diseases at the National
Institutes of Health (5 K23AI07759 to David Adler). The funding
source had no involvement in the study design, data analysis
and interpretation, or writing of this report.
D. Adler et al. / International Journal of Infectious Diseases 33 (2015) 219–221 221References
1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between
human papillomavirus and cervical cancer. J Clin Pathol Apr 2002;55(4):244–65.
2. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of
human carcinogens–Part B: biological agents. Lancet Oncol Apr 2009;10(4):
321–2.
3. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervi-
covaginal papillomavirus infection in young women. The New England journal of
medicine Feb 12 1998;338(7):423–8.
4. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al.
Persistent human papillomavirus infection as a predictor of cervical intrae-
pithelial neoplasia. Jama Dec 26 2001;286(24):3106–14.
5. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital
human papillomavirus infection as a risk factor for persistent cervical dysplasia.
Journal of the National Cancer Institute Sep 20 1995;87(18):1365–71.
6. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ,
Risse EK, et al. Relation of human papillomavirus status to cervical lesions andconsequences for cervical-cancer screening: a prospective study. Lancet Jul 3
1999;354(9172):20–5.
7. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, et al. Type-
speciﬁc persistence of human papillomavirus DNA before the development
of invasive cervical cancer. The New England journal of medicine Nov 25
1999;341(22):1633–8.
8. From the Centers for Disease Control and Prevention. 1993 revised classiﬁcation
system for HIV infection and expanded surveillance case deﬁnition for AIDS
among adolescents and adults. Jama. Feb 10 1993;269(6):729-730.
9. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright Jr TC. Human
papillomavirus infection in women infected with the human immunodeﬁcien-
cy virus.[see comment]. New England Journal of Medicine Nov 6 1997;337(19):
1343–9.
10. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al.
American Cancer Society, American Society for Colposcopy and Cervical Pa-
thology, and American Society for Clinical Pathology screening guidelines for
the prevention and early detection of cervical cancer. Am J Clin Pathol Apr
2012;137(4):516–42.
